Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 1/2020

25.02.2020 | Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Nutrition in Cholestatic Liver Disease

verfasst von: Daniela Goyes, Christopher J. Danford, Hirsh D. Trivedi, Alan Bonder

Erschienen in: Current Hepatology Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cholestatic liver disease, including primary biliary cholangitis and primary sclerosing cholangitis, can be associated with numerous extrahepatic complications. Of these, malnutrition can negatively impact quality of life in these patients. Achieving nutritional optimization in patients with cholestatic liver disease is an essential component in the overall management of the disease.

Recent Findings

Through various mechanisms, including abnormalities in bile acid metabolism, malabsorption, anorexia, and increased metabolic rate, chronic malnutrition in cholestatic liver disease can lead to vitamin, mineral, and protein deficiencies. This in turn can result in complications including osteoporosis and fractures, coagulopathy, skin, and neurologic changes. In addition, protein deficiency can worsen ascites and encephalopathy and promote sarcopenia, which increases morbidity and mortality. Such sequelae, which are often more pronounced in those with cirrhosis, highlight the importance of addressing nutritional status early on in these patients.

Summary

Monitoring and replacing essential vitamins and minerals is crucial in preventing complications associated with nutritional deficiencies. Ensuring adequate caloric and protein intake may reduce the overall morbidity associated with cholestatic liver disease. We herein summarize important concepts and management strategies of optimizing nutrition in cholestatic liver disease.
Literatur
1.
2.
Selberg O, Böttcher J, Tusch G, Pichlmayr R, Henkel E, Müller MJ. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology. 1997;25(3):652–7.CrossRefPubMed
3.
Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front Neurosci. 2017;11:617.CrossRefPubMedPubMedCentral
4.
Muñoz SJ, Heubi JE, Balistreri WF, Maddrey WC. Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology. 1989;9(4):525–31.CrossRefPubMed
5.
Terziroli Beretta-Piccoli B, et al. The challenges of primary biliary cholangitis: what is new and what needs to be done. J Autoimmun. 2019;105:102328.CrossRefPubMed
6.
Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis - Aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48(SUPPL. 1):38–57.CrossRef
7.
Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol. 2001;96(9 SUPPL):2745–50.CrossRefPubMed
8.
Roberta RHW, Jorgensen A, Lindor KD, Sartin JS, LaRusso NF. Serum lipid and fat-soluble vitamin levels.pdf. J Clin Gastroenterol. 1995;20(3):215–9.CrossRef
9.
Floreani A, Baragiotta A, Martines D, Naccarato R, D’Odorico A. Plasma antioxidant levels in chronic cholestatic liver diseases. Aliment Pharmacol Ther. 2000;14(3):353–8.CrossRefPubMed
10.
Freund C, Gotthardt DN. Vitamin a deficiency in chronic cholestatic liver disease: is vitamin a therapy beneficial? Liver Int. 2017;37(12):1752–8.CrossRefPubMed
11.
Chiu M, Dillon A, Watson S. Vitamin a deficiency and xerophthalmia in children of a developed country. J Paediatr Child Health. 2016;52(7):699–703.CrossRefPubMed
12.
Walt RP, Kemp CM, Lyness L, Bird AC, Sherlock S. Vitamin a treatment for night blindness in primary biliary cirrhosis. Br Med J. 1984;288(6423):1030–1.CrossRef
13.
14.
Knight RE, Bourne AJ, Newton M, Black A, Wilson P, Lawson MJ. Neurologic syndrome associated with low levels of vitamin E in primary biliary cirrhosis. Gastroenterology. 1986;91(1):209–11.CrossRefPubMed
15.
Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology. 1989;96(2 Pt 1):479–86.CrossRefPubMed
16.•
Assis DN. Chronic complications of cholestasis: evaluation and management. Clin Liver Dis. 2018;22(3):533–44. Addresses the common chronic complications for patients with PBC, its evaluation and management. CrossRefPubMed
17.
Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology. 1988;95(3):787–92.CrossRefPubMed
18.
Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology. 2002;36(4 Pt 1):895–903.CrossRefPubMed
19.
Guañabens N, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005;42(4):573–7.CrossRefPubMed
20.•
Danford CJ, Trivedi HD, and Bonder A, “Bone health in patients with liver diseases,” J Clin Densitom 2019. Highlights the benefit of a timely diagnosis, effective risk factor modification, and treatment of osteoporosis in chronic liver disease.
21.•
Trivedi HD, Tapper EB. Interventions to improve physical function and prevent adverse events in cirrhosis. Gastroenterol Rep. 2018;6(1):13–20. Frailty, the major complication of cirrhosis. Identification, prevention and treatment. CrossRef
22.
Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125(3):941–66.CrossRefPubMed
23.
Kazi TG, Kolachi NF, Afridi HI, Kazi NG, Sirajuddin, Naeemullah, et al. Effects of mineral supplementation on liver cirrhotic/cancer male patients. Biol Trace Elem Res. 2012;150(1–3):81–90.CrossRefPubMed
24.•
Danford CJ, et al. Osteoporosis in primary biliary cholangitis. Prz Gastroenterol. 2018;24(31):3513–20. Outlines what is known regarding the pathogenesis of bone disease in PBC and summarizes current and emerging therapies.
25.
Nishikawa H, et al. Serum zinc concentration and sarcopenia: a close linkage in chronic liver diseases. J Clin Med. 2019;8(3):336.CrossRefPubMedCentral
26.
27.
Al-Bader A, Abul H, Hussain T, Al-Moosawi M, Mathew TC, Dashti H. Selenium and liver cirrhosis. Mol Cell Biochem. 1998;185(1–2):1–6.CrossRefPubMed
28.
Kumar N, Gross JB, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology. 2004;63(1):33–9.CrossRefPubMed
29.
Wicks C, Bray GP, Williams R. Nutritional assessment in primary biliary cirrhosis: the effect of disease severity. Clin Nutr. 1995;14(1):29–34.CrossRef
30.•
Shergill R, Syed W, Rizvi SA, Singh I. Nutritional support in chronic liver disease and cirrhotics. World J Hepatol. 2018;27(10):685–94. Reviews the pathophysiology of liver disease, etiology, and management of nutrition. CrossRef
31.
Ludwig J, Idiopathic adulthood ductopenia: an update in Mayo Clinic Proceedings, 1998, 73(3):285–291.
32.••
Merli M, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–93. Screening, assessment and principles of nutritional management in specific settings such as hepatic encephalopathy, cirrhotic patients with bone disease, and patients undergoing liver surgery or transplantation. CrossRef
33.
Cosman F, de Beur SJ, LeBoff M, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.CrossRefPubMedPubMedCentral
34.
Diglio DC, Fernandes SA, Stein J, Azeredo-da-Silva A, de Mattos AA, and Tovo CV, Role of zinc supplementation in the management of chronic liver diseases: a systematic review and meta-analysis. Ann Hepatol 2019.
35.
36.••
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394–419. The 2018 updated guidance on PBC includes updates on etiology and diagnosis, role of imaging, clinical manifestations, and treatment of PBC since 2009. PubMed
37.••
Hirschfield GM, et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. Summarises the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC. CrossRef
38.
Ezaz G, Murphy SL, Mellinger J, Tapper EB. Increased morbidity and mortality associated with falls among patients with cirrhosis. Am J Med. 2018;131(6):645–650.e2.CrossRefPubMed
39.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.CrossRef
40.
41.•
Tapper EB, Derstine B, Baki J, Su GL. Bedside measures of frailty and cognitive function correlate with sarcopenia in patients with cirrhosis. Dig Dis Sci. 2019;64(12):3652–9. Evaluates the correlations between frailty measures and muscle indices from computed tomography. CrossRefPubMed
42.•
Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology. 2017;65(3):1044–57. Presents key issues, tools, and clinical options to enhance the practice of nutrition screening and assessment in patients with cirrhosis. CrossRefPubMed
43.
Álvares-Da-Silva MR, Reverbel Da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition. 2005;21(2):113–7.CrossRefPubMed
44.
Vidas NA. Primary biliary cirrhosis and primary sclerosing cholangitis and nutrition. Adv Nutr Diet Gastroenterol. 2014;2014:273–9.
45.
Rinawi F, et al. Fat malabsorption due to bile acid synthesis defect. Isr Med Assoc J. 2015;17(3):190–2.PubMed
46.
Krähenbühl L, Lang C, Lüdes S, Seiler C, Schäfer M, Zimmermann A, et al. Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int. 2003;23(2):101–9.CrossRefPubMed
47.•
Palmer LB, Kuftinec G, Pearlman M, Green CH. Nutrition in Cirrhosis. Curr Gastroenterol Rep. 2019;21:8. Malnutrition screening tools, and common macronutrient and micronutrient deficiencies encountered in individuals with chronic liver disease and their impact on morbidity and mortality. CrossRef
48.
Taylor BE et al., 2016 ASPEN Guidelines 44:2. 2016.
49.
Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25(2):285–94.CrossRefPubMed
Metadaten
Titel
Nutrition in Cholestatic Liver Disease
verfasst von
Daniela Goyes
Christopher J. Danford
Hirsh D. Trivedi
Alan Bonder
Publikationsdatum
25.02.2020
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 1/2020
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-020-00511-3

Weitere Artikel der Ausgabe 1/2020

Current Hepatology Reports 1/2020 Zur Ausgabe

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

The Role of Nutrition in the Pathogenesis and Treatment of Alcohol-Related Liver Disease

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

What Diet Should I Recommend My Patient with Hepatic Encephalopathy?

Fatty Liver Disease (V Ajmera, Section Editor)

Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH)

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Food as Therapy for Frailty

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Nutrition Management in the Critically Ill Patient with Cirrhosis

Portal Hypertension and Liver Transplantation (R Reddy, Section Editor)

Recurrent Disease After Liver Transplantation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise